Following Brian Leclaire’s last HUM Sell transaction on June 18, 2018, the stock climbed by 5.3%. In addition to Brian Leclaire, 2 other HUM executives reported Sell trades in the last month.
Based on Humana Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $14.17 billion and quarterly net profit of $355 million. In comparison, last year the company earned revenue of $13.19 billion and had a net profit of $184 million. HUM’s market cap is $41.87B and the company has a P/E ratio of 25.42. Currently, Humana Inc has an average volume of 761.3K.
Based on 10 analyst ratings, the analyst consensus is Strong Buy with an average price target of $361.20, reflecting a 17.4% upside. One of the top 25 analysts, according to TipRanks.com, recently recommended Hold HUM with a $320 price target.
The insider sentiment on Humana Inc has been negative according to 75 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Brian Leclaire’s trades have generated a -15.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana Inc. is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.